Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kroger Co (KR) Price & Performance

Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Kroger Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.09 (market cap $763.64M), while Kroger Co trades at $61.35 (market cap $36.27B). The key difference: Kroger Co is far larger — about 47.5× Ginkgo Bioworks Holdings Inc's market cap, and Kroger Co pays a 2.54% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Kroger Co for 108 Days on average.

DNAKR
Market Cap
$763.64M$36.27B
Volume
3,204,1778,301,523
Sector
HealthConsumer Staples
52-Week High
$15.83$75.60
52-Week Low
$5.48$55.53
Typical Hold Time
7 Days108 Days
Enterprise Value
$865.59M$57.69B
Dividend Yield
—2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.

The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.

Kroger Co

Kroger (KR) trades at $59.25, up 1.44% with a bullish technical signal. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, supported by positive cash flow trends. Recent earnings beat expectations in two of the last three quarters, while analysts maintain a Moderate Buy consensus with a $70.62 price target. The company continues digital growth initiatives and maintains dividend payments.

Kroger presents a value opportunity with low P/S ratio (0.25) and consistent profitability, though near-term risks include integration challenges from acquisitions and softer sales guidance. The stock's current price near support at $58 offers potential upside to analyst targets, balanced by competitive pressures in the grocery sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
KR
76% Buy24% Sell
Avg holding period · 108 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Kroger Co

Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.

Read more on KR →